External broker reports(aggregated public sources), Canaccord Genuity

Canaccord Genuity

Canaccord Genuity Group Inc. is a leading independent investment bank with operations in North America, UK & Europe and Asia-Pacific. Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<div><ul><li>We are initiating coverage of Opthea Limited (OPT-ASX) with a BUY rating and a price target of $1.25. OPT is a Phase III biopharmaceutical company focused on developing drugs for two opthalmic disorders, wet AMD (age related macular degeneration) and DME (diabetic macular oedema).</li><li>There are gaps in the current standard of care (SoC) that anti-VEGF therapies (VEGF-A inhibitors) can provide with regard to the extent of the VEGF pathway inhibition and efficacy.</li><li>Lead asset, sozinibercept (OPT-302), is a biologic inhibitor designed to trap VEGF-C/D. </li></ul></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We are initiating coverage of Opthea Limited (OPT-ASX) with a BUY rating and a price target of $1.25. OPT is a Phase III biopharmaceutical company focused on developing drugs for two opthalmic disorders, wet AMD (age related macular degeneration) and DME (diabetic macular oedema).There are gaps in the current standard of care (SoC) that anti-VEGF therapies (VEGF-A inhibitors) can provide with regard to the extent of the VEGF pathway inhibition and efficacy.Lead asset, sozinibercept (OPT-302), is a biologic inhibitor designed to trap VEGF-C/D. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Opthea Limited - Eye on the Prize: Zooming in on OPT-302

Opthea Ltd

Opthea Limited - Eye on the Prize: Zooming in on OPT-302